For trastuzumab and HER2-targeted therapies, HER2-positive breast cancer (EBC) patients can detect an increase in hypersensitive troponin at 3 months after initiation of cancer therapy and could predict the development of left ventricular heart disease (40). Here, ERBB2 is linked to breast cancer.